3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
75
Phase 1/2
30
Phase NA
28
Phase 2
23
Phase 3
6
Phase EARLY_PHASE1
1
Phase 4
1
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
13
Breast
2
Other
1
Head & Neck
1
Genitourinary
1
Conditions
Prostatic Neoplasms
118
Urinary Bladder Neoplasms
27
Carcinoma, Renal Cell
25
Kidney Neoplasms
19
Neoplasms
14
Neoplasm Metastasis
9
Breast Neoplasms
9
Non-Muscle Invasive Bladder Neoplasms
8
Prostatic Hyperplasia
5
Pain
5
Lung Neoplasms
5
Liver Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Carcinoma, Hepatocellular
4
Urologic Neoplasms
3
Stomach Neoplasms
3
Recurrence
3
Prostatic Neoplasms, Castration-Resistant
3
Multiple Myeloma
3
Kidney Diseases
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Tobacco Use Disorder
2
Small Cell Lung Carcinoma
2
Prostatic Diseases
2
Prostate Cancer Metastatic
2
Pancreatic Neoplasms
2
Interventions
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Endometrial Neoplasms
×
Genitourinary
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled